
==== Front
Diabetol Metab Syndr
Diabetol Metab Syndr
Diabetology & Metabolic Syndrome
1758-5996
BioMed Central London

39294664
1452
10.1186/s13098-024-01452-3
Research
Evaluation of serum irisin level and severity of erectile dysfunction in diabetic males: a cross sectional prospective study
Ragab Ahmed 1
Sayed Ahmed Reda 2
http://orcid.org/0000-0003-1918-5132
GamalEl Din Sameh Fayek samehfayek@kasralainy.edu.eg

3
Zeidan Ashraf 3
Ewis Faten Fathi 4
Hamed Mostafa Ahmed 1
1 https://ror.org/05pn4yv70 grid.411662.6 0000 0004 0412 4932 Department of Andrology, Sexology and STDs, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt
2 https://ror.org/05pn4yv70 grid.411662.6 0000 0004 0412 4932 Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt
3 https://ror.org/03q21mh05 grid.7776.1 0000 0004 0639 9286 Department of Andrology, Sexology and STDs, KasrAlainy Faculty of Medicine, Cairo University, Al-Saray Street, El Manial, Cairo, 11956 Egypt
4 Beni-Suef Mental Health Hospital, Beni-Suef, Egypt
19 9 2024
19 9 2024
2024
16 23321 4 2024
20 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Background

Irisin is an exercise-induced myokine that alleviates endothelial dysfunction and reduces insulin resistance in type 2 diabetes mellitus (T2DM). The current study aimed to assess the serum level of irisin in T2DM men with erectile dysfunction (ED) compared to T2DM patients with normal erectile function and healthy controls, as well as investigate the association between serum irisin level and the severity of ED in T2DM patients.

Patients and methods

A cross-sectional study was conducted on 90 males, divided into three groups: 32 T2DM patients with ED, 24 T2DM patients without ED, and 34 healthy controls. Socio-demographic characteristics and scores of the validated Arabic version of the international Index of Erectile Function-5 (ArIIEF-5), Generalized Anxiety Disorder-7 (GAD-7) and Patient Health Questionnaire-9 (PHQ-9) were obtained. Furthermore, routine laboratory tests employed for diabetes monitoring and serum levels of total testosterone and irisin were assessed within these groups.

Results

T2DM men with ED had significantly lower serum levels of irisin and testosterone, as well as a lower ArIIEF-5 score, but their GAD-7 and PHQ-9 scores were significantly higher than those without ED or controls (p < 0.001). Among T2DM men, serum irisin levels positively associated with ArIIEF-5 scores and serum testosterone (r = 0.413, p = 0.002; r = 0.936, p < 0.001, respectively) but negatively associated with glycosylated hemoglobin levels (r = -0.377, p = 0.004). Multivariate regression analysis to predict ED in T2DM patients found that GAD-7 score was the only most significant predictor for ED (ꞵ = − 1.176, standard error = 0.062, p < 0.001).

Conclusion

The current study had demonstrated that irisin positively correlated with the ArIIEF-5 and serum testosterone but negatively correlated with HbA1c in T2DM men. Nevertheless, further validation of these findings is necessary through cohort studies.

Supplementary Information

The online version contains supplementary material available at 10.1186/s13098-024-01452-3.

Keywords

Type 2 diabetes mellitus
Erectile dysfunction
Serum irisin
Cairo UniversityOpen access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).

issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Erectile dysfunction (ED) is defined as a persistent inability to attain and maintain an erection sufficient to have a satisfactory sexual performance [1]. ED is a common complication of diabetes [2]. ED is associated with a reduced quality of life and unfortunately occurs at an earlier age in diabetic patients compared to the general population [2]. In the European Male Ageing Study, the prevalence of moderate or severe ED was 19%, 38%, and 64% among participants who were 50–59, 60–69, and above 70 years of age, respectively [3]. Mechanisms responsible for ED due to endothelial dysfunction associated with DM and metabolic syndrome included low-grade systemic inflammation, fibrosis, and smooth muscle dysfunction. Despite this, mechanisms related to the occurrence of ED in DM and metabolic syndrome had not been fully elucidated [4]. Biological markers could help to explain these mechanisms and could be used as useful indicators for ED [5]. Irisin was a recently discovered myokine that was thought to be associated with metabolic diseases [6]. While at first it was considered to be a hormone that could only be synthesized in skeletal muscle, it was later found to be synthesized in many tissues in the body [6]. A previous in vivo study had shown that an increase in serum irisin levels could cause browning of white adipose tissues and decreased insulin resistance [7]. Moreover, the use of exogenous irisin was thought to alleviate endothelial dysfunction in type 2 diabetes (T2DM) by reducing oxidative and nitrative stresses [8].

The current study aimed to assess serum level of irisin in T2DM men with ED compared to T2DM patients with normal erectile function and healthy controls, as well as investigated the association between serum irisin level and the severity of ED in T2DM males.

Patients and methods

A cross-sectional study was conducted from July 2022 and February 2023 at the andrology department of Beni-Suef University Hospital in Beni-Suef governorate. The study involved 90 male individuals who were split into 3 groups including 32 ED patients with T2DM (Group I), 24 T2DM patients without ED, and 34 free controls (Group III). The institutional ethical committee in the faculty of medicine at Beni-Seuf University approved the work (Approval Number: FMBSUREC/07062022/Ewis). Additionally, informed consent was obtained from the participants conforming to the guidelines stated in the Helsinki Declaration of 2013 [9].

Sample size determination

G power was used to determine sample size, and a minimum of 70 patients and 18 controls made up the overall sample size. A priori analysis utilized various inputs to calculate the required sample size, including a two-tailed test, an effect size of 0.67, a α error probability of 0.05, a power of 0.70, and an allocation ratio of 4/1. The outcome was determined by the non-centrality parameter, critical t-value, and degrees of freedom. The final result indicated that a total sample size of 88 was needed, with 18 participants in the control group, 70 participants in the case group, and a real power of 0.71.

Inclusion criteria for patients

All participants were in a steady relationship with their female partners during the past 6 months. Patients were diagnosed as having T2DM according to the European Association for the Study of Diabetes (EASD) criteria [10], aged 25–65, and referred for follow-up. Patients scoring 22 or more on the Arabic version of the International Index of Erectile Function-5 (IIEF-5) [11] were assigned to T2DM patients with normal erectile function, while those scoring less than or equal to 21 were assigned to T2DM patients with ED.

Inclusion criteria for the controls

Controls encompassed healthy volunteers matched for age, sex, and body mass index (BMI).

Exclusion criteria for the patients

The study excluded individuals who had a BMI below 19 kg/m2 or above 30 kg/m2, history indicating psychogenic ED, comorbidities linked to ED [such as coronary artery disease, neurological diseases, major mental illness, thyroid dysfunction, hypogonadism, active liver disease, end-stage kidney disease, uncontrolled hypertension or hyperlipidemia]. Also, medications that impacted erectile function, cases of Peyronie's disease, a history of pelvic trauma or radical surgery, ongoing infections, or cases engaged in intense physical activity within the last week of sampling were excluded.

The study participants were subjected to the following:

All participants provided their medical and sexual histories. General and local examinations were carried out. During a structured interview, each participant was instructed to independently fill out the questionnaire provided. The participants were evaluated using the validated Arabic version of the IIEF-5 (ArIIEF-5) to determine their erectile function and ED severity [11]. Anxiety symptoms were assessed using the Arabic version of the generalized anxiety disorder-7 (GAD-7) scale [12]. Furthermore, depressive symptoms were assessed using the Arabic version of the Patient Health Questionnaire-9 (PHQ-9) [13]. Five cc venous blood sample was collected after 12 h overnight fasting (between 8 and 9 A.M before any significant physical activity). The samples were processed to isolate the serum, which was then stored at – 20 °C. Standard diabetes monitoring tests including fasting plasma glucose, glycosylated hemoglobin, serum lipid profile, and hepatic and renal function panels were conducted. Furthermore, the serum samples were analyzed for total testosterone and serum irisin levels. Serum testosterone levels were measured using acommercial ELISA kit (MyBiosource, Inc., San Diego, CA,USA) according to the manufacturer’s instructions. The assay kit exhibited low coefficients of variation for both intra- and inter-assay measurements, with values below 15%. The detection range for testosterone was 0.2–80 ng/mL, and the assay demonstrated a sensitivity of < 0.1 ng/ml. For the measurement of serum irisin levels, a human irisin sandwich ELISA kit from ELK Biotechnology Co. (Denver, Colorado, USA) was employed. This kit demonstrated excellent precision with low coefficients of variation for both intra- and inter-assay measurements, with values below 8% and 10%, respectively.

The detection range for irisin was 15.7–1000 pg/mL, and the assay exhibited a sensitivity of 6.9 pg/mL.

Statistical analysis

Data were coded and entered using the statistical package for the Social Sciences (SPSS) version 28 (IBM Corp., Armonk, NY, USA). Data was summarized using mean and standard deviation for quantitative variables and frequencies and percentages for categorical variables. Normality was double-checked using the Shapiro–Wilk test and normality plots in each of the three groups. Comparisons between groups were done using analysis of variance (ANOVA) with multiple comparisons. post hoc test in normally distributed quantitative variables, while the non-parametric Kruskal–Wallis test and Mann–Whitney test were used for non-normally distributed quantitative variables. χ2 test was performed for comparing categorical data. Exact test was used instead when the expected frequency is less than 5. Correlations between quantitative variables were done using the Spearman’s correlation coefficient. The receiver operating characteristic (ROC) curve was constructed with area under curve analysis performed to detect the best cutoff value of significant parameters for the detection of ED.

Results

As illustrated in Table 1, there were no significant differences in age and BMI as well as the duration of DM and the irisin/testosterone ratio between the study groups. On the other hand, significant differences were observed among all groups regarding glycosylated hemoglobin (HbA1c), serum triglycerides (TGs), serum total cholesterol as well as the levels of serum irisin and total testosterone (Table 1).Table 1 Sociodemographic, clinical and laboratorycharacteristics of the participants

	Group I
[DM with ED]
n = 32	Group II
[DM without ED]
n = 24	Group III
[Controls]
n = 34	P value	
Mean	SD	Mean	SD	Mean	SD		
Age (years)	49.75	7.81	48.13	4.49	46.94	6.31	0.218	
DM duration (years)	6.91	3.57	6.25	3.19	-	-	0.571	
BMI (kg/m2)	24.59	2.69	23.42	2.72	23.38	2.07	0.097	
Hb A1c (%)	7.65	0.92	6.22	0.57	4.88	0.22	 < 0.001d	
Serum triglycerides (mg/dl)	149.34	8.57	140.04	10.39	133.29	16.54	 < 0.001c	
Serum total cholesterol (mg/dl)	175.47	24.79	163.42	17.87	160.71	23.26	0.024a	
Serum irisin (pg/mL)	3.21	2.80	6.03	2.94	8.18	3.05	 < 0.001c	
Serum testosterone (ng/ml)	2.30	1.41	4.40	1.92	5.52	1.45	 < 0.001c	
Irisin/Testosterone ratio	1.26	0.37	1.38	0.38	1.65	1.16	0.125	
GAD-7	12.34	2.35	4.17	1.17	2.94	0.89	 < 0.001d	
PHQ-9	6.84	3.47	3.88	1.54	2.85	0.99	 < 0.001c	
ArIIEF-5 score	12.00	3.43	22.17	0.38	22.85	0.78	 < 0.001c	
a Group I differs significantly from group III; b Group I differs significantly from group II; c Group I differs significantly from both group II and group III; d Group I differs significantly from both group II and group III, while group II also shows significant differences from group III

ArIIEF-5 Arabic version of the international index of erectile function-5, BMI body mass index, DM diabetes mellitus, GAD-7 generalized anxiety disorder-7, HbA1c glycosylated hemoglobin, PHQ-9 patient health questionnaire-9

Regarding GAD-7 and PHQ-9 scores, T2DM patients with ED had significantly higher scores compared to the other groups (Table 1). In contrast, T2DM patients with ED had significantly lower scores of the ArIIEF-5 compared to the other groups (Table 1). The current study revealed significant positive correlations between serum irisin level, ArIIEF-5, DM duration and serum testosterone (r = 0.413, 0.293, 0.936, respectively) (Table 2, Fig. 1). On the other hand, there were significant negative correlations between serum irisin level and HbA1c and GAD-7 (r = − 0.377, − 0.435, respectively). Furthermore, significant positive correlations were found between serum testosterone, ArIIEF-5 and DM duration (r = 0.453 and 0.370, respectively) (Table 2). Meanwhile, there were statistically significant negative correlations between serum testosterone and HbA1c, TG, albumin/creatinine ratio, and GAD-7 (r = 0.408, − 0.269 and − 0.462, respectively) (Table 2). ROC analysis was conducted to predict the occurrence of ED in T2DM patients. The serum irisin biomarker had a cutoff value of < 3.755 ng/ml, with a sensitivity of 84.4% and a specificity of 75%, resulting in an AUC of 0.822 (Fig. 2). On the other hand, serum testosterone had a cutoff value of < 2.53 ng/ml, with a sensitivity of 81.3% and a specificity of 83.3%, resulting in an AUC of 0.834 (Fig. 2). Multivariate regression analysis to predict ED in T2DM patients found that GAD-7 score was the only most significant predictor for ED (ꞵ = − 1.176, standard error = 0.062, p < 0.001). In contrast, TGs and cholesterol and PHQ-9 were not significant predictors for ED in those patients (β = 0.034, standard error = 0.584, p = 0.561; β = 0.026, standard error = 0.493, p = 0.624; ꞵ = − 0.09, standard error = -– 1.28, p = 0.206, respectively).Table 2 Correlations between serum irisin, testosterone, irisin-to-testosterone ratio, ArIIEF-5 scores, and different parameters among diabetic patients (n = 56)

	Serum Irisin	Serum testosterone	Irisin/T ratio	ArIIEF-5 score	
Correlation coefficient	P value	Correlation coefficient	P value	Correlation coefficient	P value	Correlation coefficient	P value	
ArIIEF-5 score	0.413	0.002	0.453	 < 0.001	− 0.027	0.842	1.000		
DM duration(years)	0.293	0.028	0.370	0.005	0.091	0.504	− 0.163	0.229	
BMI (kg/m2)	− 0.169	0.213	− 0.122	0.371	− 0.152	0.263	− 0.274	0.041	
Hb A1c (%)	− 0.377	0.004	− 0.408	0.002	− 0.006	0.968	− 0.553	 < 0.001	
Triglycerides(mg/dl)	− 0.255	0.058	− 0.269	0.045	− 0.080	0.556	− 0.434	0.001	
Cholesterol(mg/dl)	− 0.095	0.488	− 0.142	0.296	0.181	0.182	− 0.357	0.007	
Serum Creatinine (mg/dl)	− 0.194	0.153	− 0.229	0.089	− 0.031	0.820	− 0.279	0.037	
ACR	− 0.302	0.024	− 0.320	0.016	− 0.008	0.956	− 0.450	0.001	
GAD-7	− 0.435	0.001	− 0.462	 < 0.001	− 0.025	0.855	− 0.902	 < 0.001	
PHQ-9	− 0.224	0.096	− 0.229	0.090	0.045	0.739	− 0.650	 < 0.001	
ACR albumin to creatinine ratio, BMI body mass index, GAD-7 generalized anxiety disorder-7, HbA1c glycosylated hemoglobin, ArIIEF-5 Arabic version of the international index of erectile function-5, PHQ-9 patient health questionnaire-9

Fig. 1 shows correlation between testosterone and irsin in T2DM men

Fig. 2 ROC curve for detection of erectile dysfunction in in T2DM patients using irisin and serum testosterone

Discussion

The present study revealed that T2DM patients with ED exhibited significantly lower circulating serum irisin levels. A previous study had presented conflicting findings regarding the alterations in circulating serum irisin levels among individuals with T2DM, gestational diabetes mellitus, and type 1 diabetes mellitus [14].

Previous studies had indicated that diabetic patients had lower irisin levels in comparison to controls [15, 16]. In our study, the average age of the diabetic patients with ED was 49.75 years. This finding strongly supports the notion that age plays a significant role in the occurrence of ED [17]. Remarkably, patients with a short duration of T2DM might be affected, as was evident from previous studies that included males < 45 years of age [18, 19]. Moreover, the current study showed that the presence of DM was associated with more severe ED as well as lower testosterone levels. Nevertheless, an earlier study indicated no differences between T2DM patients with or without metabolic syndrome regarding ED [19, 20]. Furthermore, the present data suggest that worse glycemic control is associated with ED. Indeed, higher HbA1c levels had been correlated with ED in a previous report [21]. Furthermore, poor glycemic control had been associated with worse clinical outcomes and the emergence of many diabetic complications [22]. Through distinct pathophysiologic mechanisms, micro-angiopathy and macro-angiopathy might emerge with subsequent occurrence of ED in diabetic patients alongside autonomic neuropathy [23]. Moreover, our results revealed that age, duration of DM and triglyceride levels significantly associated with ED, as well as low irisin level, which matched a previous study [24]. Additionally, DM exerted qualitative, quantitative, and kinetic abnormalities on lipoproteins and increased TG content as well as glycation of apolipoproteins [25]. Circulating irisin was significantly reduced in T2DM patients compared with healthy controls [15], which could be seen in line with our results. Our study demonstrated that reduced serum irisin levels were independently associated with elevated HbA1c. This finding might be explained as follows.

Firstly, a negative association between serum irisin and hyperglycemia and triglyceridemia as well as visceral adiposity in T2DM patient had been demonstrated by Kurdiova et al. [26]. In similar trend, a previous study showed that serum irisin directly induced glucose and fatty acid uptake in human muscles via the AMPK pathway [6]. Moreover, the over-expression of this myokine was sufficient to promote energy expenditure and alleviate insulin resistance in a diabetic animal model [7]. Further, a previous study reported that irisin played a novel role in sustaining endothelial homoeostasis through the promotion of human umbilical vein endothelial cell proliferation via the extracellular signal-regulated ERK signaling pathway [27]. Consistently, a modern study that was conducted on mice had revealed that serum irisin had protective effects on endothelia in type 2 diabetes, partially through reducing oxidative/nitrative stress and inhibiting activation of PKC-β/ NADPH oxidase and NF-κB/iNOS pathways [28]. Thus, in view of the aforementioned findings it could be postulated that irisin might be effective in the treatment of diabetic vascular complications [28]. Regarding the current results, irisin levels were found to be significantly lower among T2DM individuals with ED when compared to those with normal erectile function. This finding suggests that irisin can potentially have a protective impact on endothelial function that could be seen in alignment with the aforementioned studies [8, 27, 28]. Furthermore, Zhang et al. [29] suggested that irisin might be a possible marker of macrovascular disease in T2DM patients. A modern study had demonstrated that irisin played an important role in maintaining endothelial cell function, and low levels of irisin led to endothelial dysfunction and an increased incidence of atherosclerosis [30]. Furthermore, a previous study had indicated that irisin could mitigate endothelial damage by suppressing inflammation and oxidative stress [8].

Remarkably, the current study had demonstrated a positive correlation between serum irisin and serum testosterone level that could be seen in line with two previous studies [31, 32]. However, there was no significant association between serum irisin level and duration of DM in the current study. This lack of association may be attributed to the limited size of our study sample. Similarly, another study also failed to find a significant relationship between diabetes duration and ED [33]. Quite the reverse, previous studies demonstrated significant negative correlations [34, 35]. In the same context, a recent study showed that the risk of ED increased with DM duration of more than 10 years as well as being uncontrolled [36]. Furthermore, the present study revealed a negative correlation between serum irisin and ArIIEF-5, PHQ-9, and GAD-7 scores. This observation aligns with earlier studies conducted by Mallis et al. [37] and Yang et al. [38]. Consistently, this could be seen in agreement with Ragab et al. [39] who revealed that serum nesfatin 1 in ED diabetic patients significantly correlated with GAD-7. Admittedly, the current study had some shortcomings, including a small sample size and a brief duration of monitoring, which may be considered substantial limitations.

Remarkably, the current study had demonstrated a positive correlation between serum irisin and serum testosterone level that could be seen in line with two previous studies [31, 32]. However, there was no significant association between serum irisin level and duration of DM in the current study. This lack of association may be attributed to the limited size of our study sample. Similarly, another study also failed to find a significant relationship between diabetes duration and ED [33]. Quite the reverse, previous studies demonstrated significant negative correlations [34, 35]. In the same context, a recent study showed that the risk of ED increased with DM duration of more than 10 years as well as being uncontrolled [36]. Furthermore, the present study revealed a negative correlation between serum irisin and ArIIEF-5, PHQ-9, and GAD-7 scores. This observation aligns with earlier studies conducted by Mallis et al. [37] and Yang et al. [38]. Consistently, this could be seen in agreement with Ragab et al. [39] who revealed that serum nesfatin 1 in ED diabetic patients significantly correlated with GAD-7. Admittedly, the current study had some shortcomings, including a small sample size and a brief duration of monitoring, which may be considered substantial limitations.

Conclusion

The current study had demonstrated that irisin positively correlated with the ArIIEF-5 and serum testosterone but negatively correlated with HbA1c in T2DM men. Nevertheless, further validation of these findings is necessary through cohort studies.

Supplementary Information

Supplementary Material 1.

Acknowledgements

Not applicable.

Author contributions

A.R.: developed conception and study design and drafted the manuscript A.Z. and F.F.E. and M.A.: recruited the cases and performed the study statistics A.R.: performed the lab work S.F.G.: drafted the manuscript and critically revised the data.

Funding

Open access funding provided by The Science, Technology & Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB). This work did not receive any fund.

Availability of data and materials

The data that support the fndings of this study are available from the cor responding author upon reasonable request.

Declarations

Ethics approval and consent to participate

All procedures performed were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the local ethical committee. Informed consent was obtained from all individual participants included in the study.

Consent for publication

All authors agree to sign any required consent for publication.

Competing interests

The authors declare no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. NIH Consensus Conference. Impotence. NIH consensus development panel on impotence. JAMA.1993;270:83–90.
2. Saigal CS Wessells H Pace J Schonlau M Wilt TJ Urologic Diseases in America Project. Predictors and prevalence of erectile dysfunction in a racially diverse population Arch Intern Med 2006 166 2 207 212 10.1001/archinte.166.2.207 16432090
Saigal CS, Wessells H, Pace J, Schonlau M, Wilt TJ. Urologic Diseases in America Project. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med. 2006;166(2):207–12. 10.1001/archinte.166.2.207.16432090
3. Corona G Lee DM Forti G O'Connor DB Maggi M O'Neill TW Pendleton N Bartfai G Boonen S Casanueva FF Finn JD Giwercman A Han TS Huhtaniemi IT Kula K Lean ME Punab M Silman AJ Vanderschueren D Wu FC EMAS Study Group. Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS) J Sex Med 2010 7 4 Pt 1 1362 1380 10.1111/j.1743-6109.2009.01601.x.Epub 19929914
Corona G, Lee DM, Forti G, O’Connor DB, Maggi M, O’Neill TW, Pendleton N, Bartfai G, Boonen S, Casanueva FF, Finn JD, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean ME, Punab M, Silman AJ, Vanderschueren D, Wu FC. EMAS Study Group. Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS). J Sex Med. 2010;7(4 Pt 1):1362–80. 10.1111/j.1743-6109.2009.01601.x.Epub.19929914
4. Hou N Du G Han F Zhang J Jiao X Sun X Irisin regulates heme oxygenase-1/adiponectin axis in perivascular adipose tissue and improves endothelial dysfunction in diet-induced obese mice Cell PhysiolBiochem 2017 42 2 603 614 10.1159/000477864
Hou N, Du G, Han F, Zhang J, Jiao X, Sun X. Irisin regulates heme oxygenase-1/adiponectin axis in perivascular adipose tissue and improves endothelial dysfunction in diet-induced obese mice. Cell PhysiolBiochem. 2017;42(2):603–14. 10.1159/000477864.
5. Robinson M Boissoneault J Sevel L Letzen J Staud R The effect of base rate on the predictive value of brain biomarkers J Pain 2016 17 6 637 641 10.1016/j.jpain.2016.01.476 27066772
Robinson M, Boissoneault J, Sevel L, Letzen J, Staud R. The effect of base rate on the predictive value of brain biomarkers. J Pain. 2016;17(6):637–41. 10.1016/j.jpain.2016.01.476.27066772
6. Huh JY Panagiotou G Mougios V Brinkoetter M Vamvini MT Schneider BE Mantzoros CS FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise Metabolism 2012 61 12 1725 1738 10.1016/j.metabol.2012.09.002 23018146
Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, Mantzoros CS. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism. 2012;61(12):1725–38. 10.1016/j.metabol.2012.09.002.23018146
7. Boström P Wu J Jedrychowski MP Korde A Ye L Lo JC Rasbach KA Boström EA Choi JH Long JZ Kajimura S Zingaretti MC Vind BF Tu H Cinti S Højlund K Gygi SP Spiegelman BM A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis Nature 2012 481 7382 463 468 10.1038/nature10777 22237023
Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Boström EA, Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Højlund K, Gygi SP, Spiegelman BM. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481(7382):463–8. 10.1038/nature10777.22237023
8. Deng W Association of serum Irisin concentrations with presence and severity of coronary artery disease Med Sci Monit 2016 5 22 4193 4197 10.12659/msm.897376
Deng W. Association of serum Irisin concentrations with presence and severity of coronary artery disease. Med Sci Monit. 2016;5(22):4193–7. 10.12659/msm.897376.
9. World Medical Association World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects JAMA 2013 310 20 2191 2194 10.1001/jama.2013.281053 24141714
World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4. 10.1001/jama.2013.281053.24141714
10. Cosentino F Grant PJ Aboyans V 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD) Eur Heart J 2020 41 2 255 323 10.1093/eurheartj/ehz486 31497854
Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J. 2020;41(2):255–323.31497854
11. Shamloul R Ghanem H Abou-zeid A Validity of the Arabic version of the sexual health inventory for men among Egyptians Int J Impot Res 2004 16 5 452 455 10.1038/sj.ijir.3901248 15175638
Shamloul R, Ghanem H, Abou-zeid A. Validity of the Arabic version of the sexual health inventory for men among Egyptians. Int J Impot Res. 2004;16(5):452–5.15175638
12. Sawaya H Atoui M Hamadeh A Zeinoun P Nahas Z Adaptation and initial validation of the patient health questionnaire - 9 (PHQ-9) and the generalized anxiety disorder - 7 questionnaire (GAD-7) in an Arabic speaking Lebanese psychiatric outpatient sample Psychiatry Res 2016 239 245 252 10.1016/j.psychres.2016.03.030 27031595
Sawaya H, Atoui M, Hamadeh A, Zeinoun P, Nahas Z. Adaptation and initial validation of the patient health questionnaire - 9 (PHQ-9) and the generalized anxiety disorder - 7 questionnaire (GAD-7) in an Arabic speaking Lebanese psychiatric outpatient sample. Psychiatry Res. 2016;239:245–52. 10.1016/j.psychres.2016.03.030.27031595
13. Kroenke K Spitzer RL Williams JB The PHQ-9: validity of a brief depression severity measure J Gen Intern Med 2001 16 9 606 613 10.1046/j.1525-1497.2001.016009606.x 11556941
Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13. 10.1046/j.1525-1497.2001.016009606.x.11556941
14. Zhang C Ding Z Lv G Li J Zhou P Zhang J Lower irisin level in patients with type 2 diabetes mellitus: a case-control study and meta-analysis J Diabetes 2016 8 1 56 62 10.1111/1753-0407.12256 25494632
Zhang C, Ding Z, Lv G, Li J, Zhou P, Zhang J. Lower irisin level in patients with type 2 diabetes mellitus: a case-control study and meta-analysis. J Diabetes. 2016;8(1):56–62. 10.1111/1753-0407.12256.25494632
15. Choi YK Kim MK Bae KH Seo HA Jeong JY Lee WK Kim JG Lee IK Park KG Serum irisin levels in new-onset type 2 diabetes Diabetes Res Clin Pract 2013 100 1 96 101 10.1016/j.diabres.2013.01.007 23369227
Choi YK, Kim MK, Bae KH, Seo HA, Jeong JY, Lee WK, Kim JG, Lee IK, Park KG. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract. 2013;100(1):96–101. 10.1016/j.diabres.2013.01.007.23369227
16. Liu JJ Wong MD Toy WC Tan CS Liu S Ng XW Tavintharan S Sum CF Lim SC Lower circulating irisin is associated with type 2 diabetes mellitus J Diabetes Complications 2013 27 4 365 369 10.1016/j.jdiacomp.2013.03.002 23619195
Liu JJ, Wong MD, Toy WC, Tan CS, Liu S, Ng XW, Tavintharan S, Sum CF, Lim SC. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications. 2013;27(4):365–9. 10.1016/j.jdiacomp.2013.03.002.23619195
17. Echeverri Tirado LC Ferrer JE Herrera AM Aging and erectile dysfunction Sex Med Rev 2016 4 1 63 73 10.1016/j.sxmr.2015.10.011 27872006
Echeverri Tirado LC, Ferrer JE, Herrera AM. Aging and erectile dysfunction. Sex Med Rev. 2016;4(1):63–73. 10.1016/j.sxmr.2015.10.011.27872006
18. Kouidrat Y Pizzol D Cosco T Thompson T Carnaghi M Bertoldo A Solmi M Stubbs B Veronese N High prevalence of erectile dysfunction in diabetes: a systematic review and meta-analysis of 145 studies Diabet Med 2017 34 9 1185 1192 10.1111/dme.13403 28722225
Kouidrat Y, Pizzol D, Cosco T, Thompson T, Carnaghi M, Bertoldo A, Solmi M, Stubbs B, Veronese N. High prevalence of erectile dysfunction in diabetes: a systematic review and meta-analysis of 145 studies. Diabet Med. 2017;34(9):1185–92. 10.1111/dme.13403.28722225
19. Wang CC, Chancellor MB, Lin JM, Hsieh JH, Yu HJ. Type 2 diabetes but not metabolic syndrome is associated with an increased risk of lower urinary tract symptoms and erectile dysfunction in men aged <45 years. BJU Int. 2010;105(8):1136–40. 10.1111/j.1464-410X.2009.08913.x
20. Aslan Y Sezgin T Tuncel A Tekdogan UY Guler S Atan A Is type 2 diabetes mellitus a cause of severe erectile dysfunction in patients with metabolic syndrome? Urology 2009 74 3 561 564 10.1016/j.urology.2009.02.073 19604566
Aslan Y, Sezgin T, Tuncel A, Tekdogan UY, Guler S, Atan A. Is type 2 diabetes mellitus a cause of severe erectile dysfunction in patients with metabolic syndrome? Urology. 2009;74(3):561–4. 10.1016/j.urology.2009.02.073.19604566
21. Giugliano F Maiorino M Bellastella G Gicchino M Giugliano D Esposito K Determinants of erectile dysfunction in type 2 diabetes Int J Impot Res 2010 22 3 204 209 10.1038/ijir.2010.1 20147958
Giugliano F, Maiorino M, Bellastella G, Gicchino M, Giugliano D, Esposito K. Determinants of erectile dysfunction in type 2 diabetes. Int J Impot Res. 2010;22(3):204–9. 10.1038/ijir.2010.1.20147958
22. Barrett EJ Liu Z Khamaisi M King GL Klein R Klein BEK Hughes TM Craft S Freedman BI Bowden DW Vinik AI Casellini CM Diabetic microvascular disease: an endocrine society scientific statement J Clin Endocrinol Metab 2017 102 12 4343 4410 10.1210/jc.2017-01922 29126250
Barrett EJ, Liu Z, Khamaisi M, King GL, Klein R, Klein BEK, Hughes TM, Craft S, Freedman BI, Bowden DW, Vinik AI, Casellini CM. Diabetic microvascular disease: an endocrine society scientific statement. J Clin Endocrinol Metab. 2017;102(12):4343–410. 10.1210/jc.2017-01922.29126250
23. Russell ND Cooper ME 50 years forward: mechanisms of hyperglycaemia-driven diabetic complications Diabetologia 2015 58 8 1708 1714 10.1007/s00125-015-3600-1 25906755
Russell ND, Cooper ME. 50 years forward: mechanisms of hyperglycaemia-driven diabetic complications. Diabetologia. 2015;58(8):1708–14. 10.1007/s00125-015-3600-1.25906755
24. Chaudhary RK Shamsi BH Tan T Chen HM Xing JP Study of the relationship between male erectile dysfunction and type 2 diabetes mellitus/metabolic syndrome and its components J Int Med Res 2016 44 3 735 741 10.1177/0300060515623122 27036148
Chaudhary RK, Shamsi BH, Tan T, Chen HM, Xing JP. Study of the relationship between male erectile dysfunction and type 2 diabetes mellitus/metabolic syndrome and its components. J Int Med Res. 2016;44(3):735–41. 10.1177/0300060515623122.27036148
25. Athyros VG Doumas M Imprialos KP Stavropoulos K Georgianou E Katsimardou A Karagiannis A Diabetes and lipid metabolism Hormones (Athens) 2018 17 1 61 67 10.1007/s42000-018-0014-8 29858856
Athyros VG, Doumas M, Imprialos KP, Stavropoulos K, Georgianou E, Katsimardou A, Karagiannis A. Diabetes and lipid metabolism. Hormones (Athens). 2018;17(1):61–7. 10.1007/s42000-018-0014-8.29858856
26. Kurdiova T Balaz M Vician M Maderova D Vlcek M Valkovic L Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies J Physiol 2014 592 1091 1107 10.1113/jphysiol.2013.264655 24297848
Kurdiova T, Balaz M, Vician M, Maderova D, Vlcek M, Valkovic L, et al. Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies. J Physiol. 2014;592:1091–107.24297848
27. Song H Wu F Zhang Y Zhang Y Wang F Jiang M Wang Z Zhang M Li S Yang L Wang XL Cui T Tang D Irisin promotes human umbilical vein endothelial cell proliferation through the ERK signaling pathway and partly suppresses high glucose-induced apoptosis PLoS ONE 2014 9 10 e110273 10.1371/journal.pone.0110273 25338001
Song H, Wu F, Zhang Y, Zhang Y, Wang F, Jiang M, Wang Z, Zhang M, Li S, Yang L, Wang XL, Cui T, Tang D. Irisin promotes human umbilical vein endothelial cell proliferation through the ERK signaling pathway and partly suppresses high glucose-induced apoptosis. PLoS ONE. 2014;9(10): e110273. 10.1371/journal.pone.0110273.25338001
28. Di Z Haichang W Jinglong Z Xiaotian Z Chao X Fuyang Z Yan L Ling Z Kun L Wenjun Y Xinliang Ma Yi L Ling T Irisin improves endothelial function in type 2 diabetes through reducing oxidative/nitrative stresses J Mol Cell Cardiol 2015 10.1016/j.yjmcc.2015.07.015
Di Z, Haichang W, Jinglong Z, Xiaotian Z, Chao X, Fuyang Z, Yan L, Ling Z, Kun L, Wenjun Y, Xinliang Ma, Yi L, Ling T. Irisin improves endothelial function in type 2 diabetes through reducing oxidative/nitrative stresses. J Mol Cell Cardiol. 2015. 10.1016/j.yjmcc.2015.07.015.
29. Zhang M Chen P Chen S Sun Q Zeng QC Chen JY Liu YX Cao XH Ren M Wang JK The association of new inflammatory markers with type 2 diabetes mellitus and macrovascular complications: a preliminary study Eur Rev Med Pharmacol Sci 2014 18 11 1567 1572 24943964
Zhang M, Chen P, Chen S, Sun Q, Zeng QC, Chen JY, Liu YX, Cao XH, Ren M, Wang JK. The association of new inflammatory markers with type 2 diabetes mellitus and macrovascular complications: a preliminary study. Eur Rev Med Pharmacol Sci. 2014;18(11):1567–72.24943964
30. Li Z Wang G Zhu YJ Li CG Tang YZ Jiang ZH Yang M Ni CL Chen LM Niu WY 2017 The relationship between circulating irisin levels and tissues AGE accumulation in type 2 diabetes patients Biosci Rep 10.1042/BSR20170213
Li Z, Wang G, Zhu YJ, Li CG, Tang YZ, Jiang ZH, Yang M, Ni CL, Chen LM, Niu WY. The relationship between circulating irisin levels and tissues AGE accumulation in type 2 diabetes patients. 2017. Biosci Rep. 10.1042/BSR20170213.
31. Assyov Y Gateva A Karamfilova V Gatev T Nedeva I Velikova T Kamenov ZA Impact of testosterone treatment on circulating irisin in men with late-onset hypogonadism and metabolic syndrome Aging Male 2020 23 5 1381 1387 10.1080/13685538.2020.1770721 32456511
Assyov Y, Gateva A, Karamfilova V, Gatev T, Nedeva I, Velikova T, Kamenov ZA. Impact of testosterone treatment on circulating irisin in men with late-onset hypogonadism and metabolic syndrome. Aging Male. 2020;23(5):1381–7. 10.1080/13685538.2020.1770721.32456511
32. Ahmad IH Mostafa ERM Mohammed SA Shipl W Soliman AA Said M Correlations between serum testosterone and irisin levels in a sample of Egyptian men with metabolic syndrome; (case-control study) Arch Physiol Biochem 2020 10.1080/13813455.2020.1808018 33086018
Ahmad IH, Mostafa ERM, Mohammed SA, Shipl W, Soliman AA, Said M. Correlations between serum testosterone and irisin levels in a sample of Egyptian men with metabolic syndrome; (case-control study). Arch Physiol Biochem. 2020. 10.1080/13813455.2020.1808018.33086018
33. Binmoammar TA Hassounah S Alsaad S Rawaf S Majeed A The impact of poor glycaemic control on the prevalence of erectile dysfunction in men with type 2 diabetes mellitus: a systematic review JRSM Open 2016 7 3 2054270415622602 10.1177/2054270415622602 26981254
Binmoammar TA, Hassounah S, Alsaad S, Rawaf S, Majeed A. The impact of poor glycaemic control on the prevalence of erectile dysfunction in men with type 2 diabetes mellitus: a systematic review. JRSM Open. 2016;7(3):2054270415622602. 10.1177/2054270415622602.26981254
34. Kumsar Ş Ciğerli Ö Hasırcı E Akay AF Peşkircioğlu L The relationship between serum irisin levels and erectile dysfunction in diabetic men (irisin and erectile dysfunction in diabetic patients) Andrologia 2021 53 2 e13959 10.1111/and.13959 33400308
Kumsar Ş, Ciğerli Ö, Hasırcı E, Akay AF, Peşkircioğlu L. The relationship between serum irisin levels and erectile dysfunction in diabetic men (irisin and erectile dysfunction in diabetic patients). Andrologia. 2021;53(2):e13959. 10.1111/and.13959.33400308
35. Shelbaya S Abu Shady MM Nasr MS Bekhet MM Mageed YA Abbas M Study of irisin hormone level in type 2 diabetic patients and patients with diabetic nephropathy Curr Diabetes Rev 2018 14 5 481 486 10.2174/1573399813666170829163442 28875825
Shelbaya S, Abu Shady MM, Nasr MS, Bekhet MM, Mageed YA, Abbas M. Study of irisin hormone level in type 2 diabetic patients and patients with diabetic nephropathy. Curr Diabetes Rev. 2018;14(5):481–6. 10.2174/1573399813666170829163442.28875825
36. Tamrakar D Bhatt DS Sharma VK Poudyal AK Yadav BK Association between erectile dysfunction and type 2 diabetes mellitus J Nepal Health Res Counc 2021 19 2 378 383 10.33314/jnhrc.v19i2.3394 34601534
Tamrakar D, Bhatt DS, Sharma VK, Poudyal AK, Yadav BK. Association between erectile dysfunction and type 2 diabetes mellitus. J Nepal Health Res Counc. 2021;19(2):378–83. 10.33314/jnhrc.v19i2.3394.34601534
37. Mallis D Moysidis K Nakopoulou E Papaharitou S Hatzimouratidis K Hatzichristou D Psychiatric morbidity is frequently undetected in patients with erectile dysfunction J Urol 2005 174 5 1913 1916 10.1097/01.ju.0000176746.73667.3c 16217344
Mallis D, Moysidis K, Nakopoulou E, Papaharitou S, Hatzimouratidis K, Hatzichristou D. Psychiatric morbidity is frequently undetected in patients with erectile dysfunction. J Urol. 2005;174(5):1913–6. 10.1097/01.ju.0000176746.73667.3c.16217344
38. Yang Y Song Y Lu Y Xu Y Liu L Liu X Associations between erectile dysfunction and psychological disorders (depression and anxiety): a cross-sectional study in a Chinese population Andrologia 2019 51 10 e13395 10.1111/and.13395 31434163
Yang Y, Song Y, Lu Y, Xu Y, Liu L, Liu X. Associations between erectile dysfunction and psychological disorders (depression and anxiety): a cross-sectional study in a Chinese population. Andrologia. 2019;51(10):e13395. 10.1111/and.13395.31434163
39. Ragab A Ahmed MH Reda Sayed A EldinAbdelbary DAK GamalEl Din SF Serum nesfatin-1 level in men with diabetes and erectile dysfunction correlates with generalized anxiety disorder-7: a prospective comparative study Andrology 2023 11 307 315 10.1111/andr.13237 35871269
Ragab A, Ahmed MH, Reda Sayed A, EldinAbdelbary DAK, GamalEl Din SF. Serum nesfatin-1 level in men with diabetes and erectile dysfunction correlates with generalized anxiety disorder-7: a prospective comparative study. Andrology. 2023;11:307–15. 10.1111/andr.13237.35871269
